We are very pleased to report positive Phase 3 results from the ILLUMINATE-A study of lumasiran.
- We are very pleased to report positive Phase 3 results from the ILLUMINATE-A study of lumasiran.
- The ILLUMINATE-A study represents the sixth positive Phase 3 study for an investigational RNAi therapeutic, and we believe it further highlights the transformational potential of this modality as a whole new class of medicines.
- Based on results from the ILLUMINATE-A study, lumasiran shows potential to substantially curb oxalate overproduction the cause of progressive kidney failure in PH1.
- Lumasiran is an investigational, subcutaneously administered RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) in development for the treatment of primary hyperoxaluria type 1 (PH1).